In addition to its unique expression in prostate cancer, PSMA is known to be expressed on the endothelial cells of neovasculature in both prostatic and non-prostatic tumors (e.g., renal cell carcinoma, and breast, lung, gastric, colorectal, pancreatic, and bladder cancers) (44, 50–52). Here, FOLH1 is linked to prostate carcinoma.